AIM ImmunoTech reports positive mid-year results for Ampligen® in pancreatic cancer, ensuring operational funding and advancing clinical trials.
Quiver AI Summary
AIM ImmunoTech Inc. has released a mid-year report highlighting its focus on advancing the clinical trials of its drug Ampligen® (rintatolimod) for pancreatic cancer treatment, in combination with AstraZeneca's Imfinzi® (durvalumab). The report indicates promising results, with no significant toxicity and improved progression-free survival (PFS) and overall survival (OS) rates among participants. CEO Thomas K. Equels emphasized the company's progress despite market challenges and noted significant achievements, including a successful equity financing that raised $8 million and extended operational funding for approximately 12 months. The company has also secured U.S. patents for manufacturing methods related to Ampligen, received orphan drug designations for pancreatic cancer in the U.S. and EU, and presented encouraging oncology data at various scientific forums. AIM aims to create a clear regulatory path and maximize the potential of Ampligen to enhance shareholder value.
Potential Positives
- Positive mid-year report indicates no significant toxicity and improved progression-free survival (PFS) and overall survival (OS) for Ampligen® in combination with AstraZeneca’s Imfinzi® for pancreatic cancer treatment.
- Raised $8.0 million in gross proceeds from a public equity offering, providing funding for operations for approximately 12 months.
- Granted U.S. and EU Orphan Drug designations for Ampligen in the treatment of pancreatic cancer, enhancing its development potential and market exclusivity.
- Resumed trading on the NYSE American, reinforcing investor confidence and visibility in the market.
Potential Negatives
- The focus on a single indication, pancreatic cancer, may limit the company's overall portfolio diversification, which could increase risk if this therapy does not achieve regulatory approval.
- The press release underscores existing significant macro and sector-related headwinds, suggesting challenges in the broader market that could negatively impact the company's performance.
- Despite raising $8 million, the financing is only expected to fund operations for about 12 months, indicating potential future liquidity challenges if further funding is not secured.
FAQ
What is the focus of AIM ImmunoTech's clinical trials?
AIM ImmunoTech is primarily focused on advancing clinical trials of Ampligen® for the treatment of pancreatic cancer.
What positive data has been reported for Ampligen®?
A mid-year report highlighted positive signs of no significant toxicity and superior progression-free survival (PFS) and overall survival (OS) rates.
How has AIM ImmunoTech strengthened its financial position?
The company closed a public equity offering, raising $8 million in gross proceeds to fund operations for approximately 12 months.
What achievements has AIM ImmunoTech recently announced?
Recent achievements include resumed trading on NYSE American, granted patents for Ampligen, and Orphan Drug designations for pancreatic cancer.
Where can I find more information about AIM ImmunoTech?
More information can be found on AIM ImmunoTech's website at aimimmuno.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AIM Insider Trading Activity
$AIM insiders have traded $AIM stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AIM stock by insiders over the last 6 months:
- THOMAS K EQUELS (CEO & President) has made 7 purchases buying 2,187,048 shares for an estimated $76,092 and 0 sales.
- TED D KELLNER purchased 1,968,504 shares for an estimated $50,000
- WILLIAM M MITCHELL purchased 196,851 shares for an estimated $5,000
- PETER W III RODINO (COO, Secretary, Gen. Counsel) purchased 500 shares for an estimated $43
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AIM Hedge Fund Activity
We have seen 10 institutional investors add shares of $AIM stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 455,615 shares (+22.9%) to their portfolio in Q1 2025, for an estimated $55,721
- CITADEL ADVISORS LLC removed 310,332 shares (-86.4%) from their portfolio in Q1 2025, for an estimated $37,953
- GEODE CAPITAL MANAGEMENT, LLC added 67,318 shares (+14.5%) to their portfolio in Q1 2025, for an estimated $8,232
- RENAISSANCE TECHNOLOGIES LLC added 57,500 shares (+22.1%) to their portfolio in Q1 2025, for an estimated $7,032
- TWO SIGMA SECURITIES, LLC removed 50,609 shares (-71.0%) from their portfolio in Q1 2025, for an estimated $6,189
- CRESCENT GROVE ADVISORS, LLC added 45,390 shares (+inf%) to their portfolio in Q1 2025, for an estimated $5,551
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 38,040 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,652
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Primary focus on pancreatic cancer
Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and OS
Bolstered cash position provides runway to fund operations for approximately 12 months
OCALA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent key financial milestones and firmly stated its focus on advancing clinical trials of Ampligen® for the treatment of pancreatic cancer, with the ultimate goal of achieving drug approval.
AIM ImmunoTech CEO Thomas K. Equels stated, “We have emerged strong despite significant macro, sector and market-related headwinds. Our perseverance, dedication to patients, belief in the potential of Ampligen and commitment to all stakeholders have enabled us to successfully navigate through an extremely challenging period. With our regained listing status, the closing of a significant equity financing and the continued advancement of our pipeline and strengthened patent estate, we are well poised to build momentum and drive value for all stakeholders.
“Our growing body of positive data with Ampligen has provided the opportunity to focus our resources and priorities to our lead indication in pancreatic cancer. We believe establishing a clear path to registration and the execution of our clinical and regulatory initiatives will unlock the full potential of this important asset and shareholder value,” added Equels.
Significant Achievements
- Resumed trading on the NYSE American;
- Closed public equity offering, raising $8.0 million in gross proceeds, which is expected to fund operations for approximately 12 months;
- Reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX (the “DURIPANC” study) (See: NCT05927142 );
- Granted U.S. patent covering methods of manufacturing therapeutic dsRNA, including Ampligen;
- Granted U.S. patent for Ampligen in combination with PD-L1 drugs for the treatment of cancer;
- Granted U.S. and EU Orphan Drug designations for pancreatic cancer;
-
Ampligen oncology data presented at scientific congresses including the Annual Meeting of the American Association of Immunologists and U.S.-Poland Science and Technology Symposium 2025;
For more information, please visit the Company’s website at aimimmuno.com .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
